Rui Avelar - 10 Aug 2021 Form 4 Insider Report for Evolus, Inc. (EOLS)

Role
Chief Medical Officer and Head of Research & Development
Signature
/s/ Jeffrey J. Plumer, as attorney-in-fact for Rui Avelar
Issuer symbol
EOLS
Transactions as of
10 Aug 2021
Net transactions value
-$159,789
Form type
4
Filing time
12 Aug 2021, 18:45:11 UTC
Next filing
26 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EOLS Common Stock Sale $159,789 -14,293 -6.4% $11.18 209,810 10 Aug 2021 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in the second quarter of 2020 and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain Restricted Stock Units.
F2 The shares were sold in multiple trades at prices ranging from $11.1762 to $11.31. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

Chief Medical Officer and Head of Research & Development